Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

Publication Name: Annals of Surgery

Author(s): Matthias Maak, MD, Iris Simon, PhD, Ulrich Nitsche, MD, Paul Roepman, PhD, Mireille Snel, MSc Annuska M. Glas, PhD

  Objectives: The aim of this study was to independently validate a genomic signature developed both to assess recurrence risk in stage II patients and to assist in treatment decisions.   Background: Adjuvant therapy is recommended for high-risk patients with … Continued

Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer

Publication Name: 2012 ASCO Gastrointestinal Cancers Symposium, JCO Abstract

Author(s): Josep Tabernero, Victor Moreno, Robert Rosenberg, Ulrich Nitsche, Thomas Bachleitner-Hofmann, Giovanni Lanza, Jeroen van den Akker, Paul Roepman, Iris Simon, Ramon Salazar; Vall d'Hebron University Hospital, Barcelona, Spain; IDIBELL, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Medizinische Universitaet Wien, Vienna, Austria; Department of Experimental and Diagnostic Medicine, Section of Anatomic Pathology, Ferrara, Italy; Agendia BV, Amsterdam, Netherlands; Institut Catala d'Oncologia, Barcelona, Spain

Background: Between 25 and 35% of stage II colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy. ColoPrint is a gene expression classifier that can predict disease relapse in patients with early-stage colorectal … Continued

The PARSC Trial, a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Publication Name: ASCO 2011 Poster

Author(s): R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall4 , J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots

Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature was validated in in-silico datasets and independent patient cohorts of stage … Continued

Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients

Publication Name: ASCO GI 2011

Author(s): R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, I. Simon, R. Bender, K. P. Janssen and H. Friess

Background: Adjuvant therapy is not routinely recommended for stage II CC patients but may be considered for high-risk patients. In this study we aim to independently validate a genomic profile that was developed to identify high-risk patients and can assist in … Continued

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

Publication Name: Journal of Clinical Oncology

Author(s): Ramon Salazar, Paul Roepman, Gabriel Capella, Victor Moreno, Iris Simon, Christa Dreezen, Adriana Lopez-Doriga, Cristina Santos, Corrie Marijnen, Johan Westerga, Sjoerd Bruin, David Kerr, Peter Kuppen, Cornelis van de Velde, Hans Morreau, Loes Van Velthuy

Purpose: This study aims to develop a robust gene expression classifier that can predict disease relapse in patients with early-stage colorectal cancer (CRC). Patients and Methods Fresh frozen tumor tissue from 188 patients with stage I to IV CRC undergoing … Continued